-+ 0.00%
-+ 0.00%
-+ 0.00%

MERCK & CO - PATIENT ENROLLMENT CONTINUES IN IDEATE-LUNG02 PHASE 3 TRIAL FOR IFINATAMAB DERUXTECAN

Reuters·09/25/2026 20:32:07